{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "33479293", "DateCompleted": {"Year": "2021", "Month": "09", "Day": "24"}, "DateRevised": {"Year": "2021", "Month": "09", "Day": "24"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "01", "Day": "21"}], "Language": ["eng"], "ELocationID": ["1914", "10.1038/s41598-021-81356-8"], "Journal": {"ISSN": "2045-2322", "JournalIssue": {"Volume": "11", "Issue": "1", "PubDate": {"Year": "2021", "Month": "Jan", "Day": "21"}}, "Title": "Scientific reports", "ISOAbbreviation": "Sci Rep"}, "ArticleTitle": "Specific egg yolk immunoglobulin as a promising non-antibiotic biotherapeutic product against Acinetobacter baumannii pneumonia infection.", "Pagination": {"StartPage": "1914", "MedlinePgn": "1914"}, "Abstract": {"AbstractText": ["Acinetobacter baumannii is a serious health threat with a high mortality rate. We have already reported prophylactic effects of IgYs raised against OmpA and Omp34 as well as against inactivated whole-cell (IWC) of A. baumannii in a murine pneumonia model. However, the infection was exacerbated in the mice group that received IgYs raised against the combination of OmpA and Omp34. The current study was conducted to propose reasons for the observed antibody-dependent enhancement (ADE) in addition to the therapeutic effect of specific IgYs in the murine pneumonia model. This phenomenon was hypothetically attributed to topologically inaccessible similar epitopes of OmpA and Omp34 sharing similarity with peptides of mice proteins. In silico analyses revealed that some inaccessible peptides of OmpA shared similarity with peptides of Omp34 and Mus musculus. Specific anti-OmpA and anti-Omp34 IgYs cross-reacted with Omp34 and OmpA respectively. Specific IgYs showed different protectivity against A. baumannii AbI101 in the murine pneumonia model. IgYs triggered against OmpA or IWC of A. baumannii were the most protective antibodies. IgY triggered against Omp34 is ranked next after those against OmpA. The lowest protection was observed in mice received IgYs raised against the combination of rOmpA and rOmp34. In conclusion, specific IgYs against OmpA, Omp34, and IWC of A. baumannii could serve as novel biotherapeutics against A. baumannii pneumonia."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biology, Shahed University, Tehran-Qom Express Way, 3319118651, Tehran, Iran."}, {"Identifier": [], "Affiliation": "Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran."}], "LastName": "Jahangiri", "ForeName": "Abolfazl", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Molecular Microbiology Research Center and Department of Biology, Shahed University, Tehran, Iran."}, {"Identifier": [], "Affiliation": "Department of Microbiology, Faculty of Medical Sciences, Shahed University, Tehran, Iran."}], "LastName": "Owlia", "ForeName": "Parviz", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biology, Shahed University, Tehran-Qom Express Way, 3319118651, Tehran, Iran. rasooli@shahed.ac.ir."}, {"Identifier": [], "Affiliation": "Molecular Microbiology Research Center and Department of Biology, Shahed University, Tehran, Iran. rasooli@shahed.ac.ir."}], "LastName": "Rasooli", "ForeName": "Iraj", "Initials": "I"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran."}], "LastName": "Salimian", "ForeName": "Jafar", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Ph.D. Student of Medical Biotechnology, Hamadan University of Medical Sciences, Hamadan, Iran."}], "LastName": "Derakhshanifar", "ForeName": "Ehsan", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biology, Shahed University, Tehran-Qom Express Way, 3319118651, Tehran, Iran."}], "LastName": "Aghajani", "ForeName": "Zahra", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Behbahan Khatam Alanbia University of Technology, Behbahan, Iran."}], "LastName": "Abdollahi", "ForeName": "Sajad", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biology Sciences, Shahid Rajaee Teacher Training University, Tehran, Iran."}], "LastName": "Khalili", "ForeName": "Saeed", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Shahed University, Tehran, Iran."}], "LastName": "Talei", "ForeName": "Daryush", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biology, Shahed University, Tehran-Qom Express Way, 3319118651, Tehran, Iran."}], "LastName": "Eslam", "ForeName": "Elham Darzi", "Initials": "ED"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Sci Rep", "NlmUniqueID": "101563288", "ISSNLinking": "2045-2322"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Bacterial Outer Membrane Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Epitopes"}, {"RegistryNumber": "0", "NameOfSubstance": "IgY"}, {"RegistryNumber": "0", "NameOfSubstance": "Immunoglobulins"}, {"RegistryNumber": "0", "NameOfSubstance": "Vaccines"}, {"RegistryNumber": "149024-69-1", "NameOfSubstance": "OMPA outer membrane proteins"}], "MeshHeadingList": [{"QualifierName": ["drug effects", "immunology", "pathogenicity"], "DescriptorName": "Acinetobacter baumannii"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["drug effects", "immunology"], "DescriptorName": "Antibody-Dependent Enhancement"}, {"QualifierName": ["antagonists & inhibitors", "immunology"], "DescriptorName": "Bacterial Outer Membrane Proteins"}, {"QualifierName": [], "DescriptorName": "Disease Models, Animal"}, {"QualifierName": ["chemistry", "immunology"], "DescriptorName": "Egg Yolk"}, {"QualifierName": ["drug effects", "immunology"], "DescriptorName": "Epitopes"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["immunology", "pharmacology"], "DescriptorName": "Immunoglobulins"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": ["drug therapy", "genetics", "immunology", "microbiology"], "DescriptorName": "Pneumonia"}, {"QualifierName": ["immunology", "pharmacology"], "DescriptorName": "Vaccines"}], "CoiStatement": "The authors declare no competing interests."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Perez F, Bonomo RA. Vaccines for Acinetobacter baumannii: thinking \u201cout of the box\u201d. Vaccine. 2014;32:2537\u20132539. doi: 10.1016/j.vaccine.2014.03.031.", "ArticleIdList": ["10.1016/j.vaccine.2014.03.031", "PMC4028134", "24662709"]}, {"Citation": "Tacconelli E, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet. Infect. Dis. 2018;18:318\u2013327. doi: 10.1016/S1473-3099(17)30753-3.", "ArticleIdList": ["10.1016/S1473-3099(17)30753-3", "29276051"]}, {"Citation": "Huang W, et al. Immunization with a 22-kDa outer membrane protein elicits protective immunity to multidrug-resistant Acinetobacter baumannii. Sci. Rep. 2016;6:20724. doi: 10.1038/srep20724.", "ArticleIdList": ["10.1038/srep20724", "PMC4745112", "26853590"]}, {"Citation": "Ballouz T, et al. Risk factors, clinical presentation, and outcome of Acinetobacter baumannii bacteremia. Front. Cell. Infect. Microbiol. 2017;7:156. doi: 10.3389/fcimb.2017.00156.", "ArticleIdList": ["10.3389/fcimb.2017.00156", "PMC5415554", "28523249"]}, {"Citation": "Neshani, A. et al. Antimicrobial peptides as a promising treatment option against Acinetobacter baumannii infections. Microbial Pathogenesis, 104238 (2020).", "ArticleIdList": ["32387392"]}, {"Citation": "Bassetti, M., Labate, L., Russo, C., Vena, A. & Giacobbe, D. R. Therapeutic options for difficult-to-treat A cinetobacter baumannii infections: a 2020 perspective. Expert Opinion on Pharmacotherapy, 1\u201311 (2020).", "ArticleIdList": ["32915685"]}, {"Citation": "Isler, B., Doi, Y., Bonomo, R. A. & Paterson, D. L. New treatment options against carbapenem-resistant Acinetobacter baumannii infections. Antimicrobial agents and chemotherapy63 (2019).", "ArticleIdList": ["PMC6325237", "30323035"]}, {"Citation": "Ahmad TA, Tawfik DM, Sheweita SA, Haroun M, El-Sayed LH. Development of immunization trials against Acinetobacter baumannii. Trials Vaccinol. 2016;5:53\u201360. doi: 10.1016/j.trivac.2016.03.001.", "ArticleIdList": ["10.1016/j.trivac.2016.03.001"]}, {"Citation": "McConnell MJ, Pach\u00f3n J. Active and passive immunization against Acinetobacter baumannii using an inactivated whole cell vaccine. Vaccine. 2010;29:1\u20135. doi: 10.1016/j.vaccine.2010.10.052.", "ArticleIdList": ["10.1016/j.vaccine.2010.10.052", "21044668"]}, {"Citation": "Luo G, et al. Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PLoS ONE. 2012;7:e29446. doi: 10.1371/journal.pone.0029446.", "ArticleIdList": ["10.1371/journal.pone.0029446", "PMC3254619", "22253723"]}, {"Citation": "KuoLee R, et al. Intranasal immunization protects against Acinetobacter baumannii-associated pneumonia in mice. Vaccine. 2015;33:260\u2013267. doi: 10.1016/j.vaccine.2014.02.083.", "ArticleIdList": ["10.1016/j.vaccine.2014.02.083", "24699469"]}, {"Citation": "Huang W, et al. OmpW is a potential target for eliciting protective immunity against Acinetobacter baumannii infections. Vaccine. 2015;33:4479\u20134485. doi: 10.1016/j.vaccine.2015.07.031.", "ArticleIdList": ["10.1016/j.vaccine.2015.07.031", "26207591"]}, {"Citation": "Asadi-Ghalehni M, et al. Cancer immunotherapy by a recombinant phage vaccine displaying EGFR mimotope: an in vivo study. Immunopharmacol. Immunotoxicol. 2015;37:274\u2013279. doi: 10.3109/08923973.2015.1027917.", "ArticleIdList": ["10.3109/08923973.2015.1027917", "25990849"]}, {"Citation": "M\u00fcller S, Schubert A, Zajac J, Dyck T, Oelkrug C. IgY antibodies in human nutrition for disease prevention. Nutr. J. 2015;14:109. doi: 10.1186/s12937-015-0067-3.", "ArticleIdList": ["10.1186/s12937-015-0067-3", "PMC4617726", "26487372"]}, {"Citation": "Kollberg H, et al. Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr. Pulmonol. 2003;35:433\u2013440. doi: 10.1002/ppul.10290.", "ArticleIdList": ["10.1002/ppul.10290", "12746939"]}, {"Citation": "Thomsen K, et al. Anti-Pseudomonas aeruginosa IgY antibodies induce specific bacterial aggregation and internalization in human polymorphonuclear neutrophils. Infect. Immun. 2015;83:2686\u20132693. doi: 10.1128/IAI.02970-14.", "ArticleIdList": ["10.1128/IAI.02970-14", "PMC4468541", "25895968"]}, {"Citation": "Thomsen K, et al. Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils. Hum. Vaccines Immunother. 2016;12:1690\u20131699.", "ArticleIdList": ["PMC4964812", "26901841"]}, {"Citation": "Thomsen K, et al. Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model. J. Cyst. Fibros. 2016;15:171\u2013178. doi: 10.1016/j.jcf.2015.08.002.", "ArticleIdList": ["10.1016/j.jcf.2015.08.002", "26303991"]}, {"Citation": "Jahangiri A, et al. Specific egg yolk antibodies (IgY) confer protection against Acinetobacter baumannii in a murine pneumonia model. J. Appl. Microbiol. 2019;126:624\u2013632. doi: 10.1111/jam.14135.", "ArticleIdList": ["10.1111/jam.14135", "30353977"]}, {"Citation": "Smani Y, McConnell MJ, Pach\u00f3n J. Role of fibronectin in the adhesion of Acinetobacter baumannii to host cells. PLoS ONE. 2012;7:e33073. doi: 10.1371/journal.pone.0033073.", "ArticleIdList": ["10.1371/journal.pone.0033073", "PMC3326023", "22514602"]}, {"Citation": "Fajardo Bonin, R. et al. Identification of immunogenic proteins of the bacterium Acinetobacter baumannii using a proteomic approach. PROTEOMICS Clin. Appl.8, 916\u2013923 (2014).", "ArticleIdList": ["24899143"]}, {"Citation": "Lin L, et al. Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes. Vaccine. 2013;31:313\u2013318. doi: 10.1016/j.vaccine.2012.11.008.", "ArticleIdList": ["10.1016/j.vaccine.2012.11.008", "PMC3557524", "23153442"]}, {"Citation": "Islam AHMS, Singh K-KB, Ismail A. Demonstration of an outer membrane protein that is antigenically specific for Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis. 2011;69:38\u201344. doi: 10.1016/j.diagmicrobio.2010.09.008.", "ArticleIdList": ["10.1016/j.diagmicrobio.2010.09.008", "21146712"]}, {"Citation": "Weber BS, Kinsella RL, Harding CM, Feldman MF. The secrets of Acinetobacter secretion. Trends Microbiol. 2017;25:532\u2013545. doi: 10.1016/j.tim.2017.01.005.", "ArticleIdList": ["10.1016/j.tim.2017.01.005", "PMC5474180", "28216293"]}, {"Citation": "Chen W. Current advances and challenges in the development of Acinetobacter vaccines. Human vaccines & immunotherapeutics. 2015;11:2495\u20132500. doi: 10.1080/21645515.2015.1052354.", "ArticleIdList": ["10.1080/21645515.2015.1052354", "PMC4635877", "26158773"]}, {"Citation": "Jahangiri A, Rasooli I, Owlia P, Fooladi AAI, Salimian J. An integrative in silico approach to the structure of Omp33-36 in Acinetobacter baumannii. Comput. Biol. Chem. 2018;72:77\u201386. doi: 10.1016/j.compbiolchem.2018.01.003.", "ArticleIdList": ["10.1016/j.compbiolchem.2018.01.003", "29414099"]}, {"Citation": "Jahangiri A, Rasooli I, Owlia P, Fooladi AAI, Salimian J. Highly conserved exposed immunogenic peptides of Omp34 against Acinetobacter baumannii: an innovative approach. J. Microbiol. Methods. 2018;144:79\u201385. doi: 10.1016/j.mimet.2017.11.008.", "ArticleIdList": ["10.1016/j.mimet.2017.11.008", "29133159"]}, {"Citation": "Wang-Lin, S. X. et al. Antibody Dependent Enhancement of Acinetobacter baumannii Infection in a Mouse Pneumonia Model. J. Pharmacol. Exp. Therapeut. (2019).", "ArticleIdList": ["30606761"]}, {"Citation": "Jahangiri A, Rasooli I, Owlia P, Fooladi AAI, Salimian J. In silico design of an immunogen against Acinetobacter baumannii based on a novel model for native structure of Outer membrane protein A. Microb. Pathog. 2017;105:201\u2013210. doi: 10.1016/j.micpath.2017.02.028.", "ArticleIdList": ["10.1016/j.micpath.2017.02.028", "28242426"]}, {"Citation": "Pirovano W, Feenstra KA, Heringa J. PRALINETM: a strategy for improved multiple alignment of transmembrane proteins. Bioinformatics. 2008;24:492\u2013497. doi: 10.1093/bioinformatics/btm636.", "ArticleIdList": ["10.1093/bioinformatics/btm636", "18174178"]}, {"Citation": "Lieberman HR. Estimating LD50 using the probit technique: a basic computer program. Drug Chem. Toxicol. 1983;6:111\u2013116. doi: 10.3109/01480548309072465.", "ArticleIdList": ["10.3109/01480548309072465", "6688047"]}, {"Citation": "Bhamidimarri, S. P. et al. A multidisciplinary approach towards identification of novel antibiotic scaffolds for Acinetobacter baumannii. bioRxiv, 306035 (2018).", "ArticleIdList": ["30554842"]}, {"Citation": "Manepalli S, et al. Characterization of a cyclophosphamide-induced murine model of immunosuppression to study Acinetobacter baumannii pathogenesis. J. Med. Microbiol. 2013;62:1747. doi: 10.1099/jmm.0.060004-0.", "ArticleIdList": ["10.1099/jmm.0.060004-0", "PMC4083505", "24000227"]}, {"Citation": "Toobak H, et al. Immune response variations to Salmonella enterica serovar Typhi recombinant porin proteins in mice. Biologicals. 2013;41:224\u2013230. doi: 10.1016/j.biologicals.2013.05.005.", "ArticleIdList": ["10.1016/j.biologicals.2013.05.005", "23796754"]}, {"Citation": "Little SF, Webster WM, Fisher DE. Monoclonal antibodies directed against protective antigen of Bacillus anthracis enhance lethal toxin activity in vivo. FEMS Immunol. Med. Microbiol. 2011;62:11\u201322. doi: 10.1111/j.1574-695X.2011.00782.x.", "ArticleIdList": ["10.1111/j.1574-695X.2011.00782.x", "21231965"]}, {"Citation": "Mohamed N, et al. Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect. Immun. 2004;72:3276\u20133283. doi: 10.1128/IAI.72.6.3276-3283.2004.", "ArticleIdList": ["10.1128/IAI.72.6.3276-3283.2004", "PMC415670", "15155630"]}, {"Citation": "Carlander D, Kollberg H, Wej\u00e5ker P-E, Larsson A. Peroral immunotheraphy with yolk antibodies for the prevention and treatment of enteric infections. Immunol. Res. 2000;21:1\u20136. doi: 10.1385/IR:21:1:1.", "ArticleIdList": ["10.1385/IR:21:1:1", "PMC7090601", "10803878"]}, {"Citation": "Kovacs-Nolan J, Mine Y. Egg yolk antibodies for passive immunity. Ann. Rev. Food Sci. Technol. 2012;3:163\u2013182. doi: 10.1146/annurev-food-022811-101137.", "ArticleIdList": ["10.1146/annurev-food-022811-101137", "22136128"]}], "ReferenceList": []}], "History": [{"Year": "2020", "Month": "5", "Day": "20"}, {"Year": "2021", "Month": "1", "Day": "5"}, {"Year": "2021", "Month": "1", "Day": "22", "Hour": "6", "Minute": "20"}, {"Year": "2021", "Month": "1", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "9", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "1", "Day": "21"}], "PublicationStatus": "epublish", "ArticleIdList": ["33479293", "PMC7820402", "10.1038/s41598-021-81356-8", "10.1038/s41598-021-81356-8"]}}], "PubmedBookArticle": []}